# hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

> **NCT06444022** · PHASE1 · WITHDRAWN · sponsor: **Nanfang Hospital, Southern Medical University**

## Conditions studied

- Acute Graft Versus Host Disease

## Interventions

- **BIOLOGICAL:** Human amniotic epithelial stem cells（hAESCs）
- **BIOLOGICAL:** placebo (cell preservation solution)

## Key facts

- **NCT ID:** NCT06444022
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The research content involving the use of hAESCs for the prevention of aGVHD after HSCT has completed the IND application for treating the said condition. Therefore, an application is submitted to terminate this research project.
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444022, "hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06444022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*